Hepion Pharmaceuticals is a biopharmaceutical company focused primarily on the clinical development and commercialization of targeted antiviral therapies with a specific focus on developing a potentially curative therapy for hepatitis B virus (HBV). Co. is developing two anti-HBV compounds with complementary mechanisms of action. Co.'s key compound, TXL™ is in development and is designed to deliver high intrahepatic concentrations of tenofovir (TFV), while minimizing off-target effects caused by high levels of circulating TFV. CRV431, Co.'s second compound for HBV, is a next-generation cyclophilin inhibitor with a structure that increases its selective index against TXL™. We show 6 historical shares outstanding datapoints in our CTRV shares outstanding history coverage, used to compute CTRV market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CTRV market cap history over the course of time is important for investors
interested in comparing CTRV's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CTRV versus a peer is one thing; comparing
CTRV market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CTRV can fluctuate over the course of history.
With this page we aim to empower investors researching CTRV by allowing them to research the CTRV market cap history. |
Free CTRV Email Alerts:
Video: The Importance of Market Cap
